Sign up Australia
Proactive Investors - Run By Investors For Investors

Small-Cap Snapshot: CTI BioPharma shares sink after late-stage trial of its cancer drug disappoints

The Phase 3 trial of its treatment for non-Hodgkin's lymphoma didn't meet the goals of the study
Small-Cap Snapshot: CTI BioPharma shares sink after late-stage trial of its cancer drug disappoints
Shares of the oncology biotech dropped by double digits

CTI BioPharma Corp (NASDAQ:CTIC) shares fell after a disappointing late-stage trial of its cancer drug. The Phase 3 trial of its treatment for non-Hodgkin's lymphoma failed to meet its main goals. The trial included more than 300 patients who had relapsed and were not eligible for stem cell transplant. Shares of the Washington-based biotech fell more than 14% to US$4.47.

Helen of Troy Ltd (NASDAQ:HELE) shares were up following a strong fiscal first quarter. The personal and household products company reported earnings of US$1.87 per share on revenue of US$354.68mln compared with analyst estimates of US$1.46 EPS on revenue of US$333.75mln. Its brand portfolio includes Revlon, Vicks, Dr. Scholl’s and Honeywell. Shares of the Bermuda-based company rose more than 13% to US$115.34 in Monday morning trading.

READ: Helen of Troy stock soars after fiscal 1Q earnings beat Street

Groupon Inc (NASDAQ:GRPN) shares jump after weekend reports that the coupon company was looking for a buyer. The company has allegedly been contacting public companies to see if there was any interest, according to a Recode report. The company has been independently run for the last 10 years. Shares of the Chicago-based company were up nearly 5% to US$4.57.

MabVax Therapeutics Holdings Inc (NASDAQ:MBVX) saw its shares nearly quadruple after news that Boehringer Ingelheim has acquired the rights to its antibody development program in a US$11mln deal. The program targets a chemical compound commonly seen on multiple solid tumor cancers. The clinical-stage biotech focuses on the development of cancer treatments. Shares of the California-based company jumped more than 280% to US$2.25.

 

Contact Lenore Fedow at [email protected]

Follow her on Twitter@LenoreMariee

 

View full CTIC profile View Profile

CTI BioPharma Corp Timeline

Related Articles

Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system
Oncoprex
Thu
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use